BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

880 related articles for article (PubMed ID: 91697)

  • 1. Evaluation of a "nude" mouse-human tumor panel as a predictive secondary screen for cancer chemotherapeutic agents.
    Bellet RE; Danna V; Mastrangelo MJ; Berd D
    J Natl Cancer Inst; 1979 Nov; 63(5):1185-8. PubMed ID: 91697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts.
    Taetle R; Rosen F; Abramson I; Venditti J; Howell S
    Cancer Treat Rep; 1987 Mar; 71(3):297-304. PubMed ID: 3815395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy of a human malignant melanoma transplanted in the nude mouse.
    Povlsen CO; Jacobsen GK
    Cancer Res; 1975 Oct; 35(10):2790-6. PubMed ID: 1157050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Application of nude mouse-human cancer xenograft system for sensitivity test of anticancer drugs].
    Fujita M; Taguchi T
    Gan To Kagaku Ryoho; 1982 Apr; 9(4):606-15. PubMed ID: 7184418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of 4'-(9-acridinylamino) methanesulfon-m-anisidide (m-AMSA, NSC 249992) on human tumors in nude mice.
    Sordillo PP; Helson L; Lesser M
    Cancer Clin Trials; 1980; 3(4):385-9. PubMed ID: 6893575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea, and L-phenylalanine mustard on B16, Cloudman S91, and Harding-Passey mouse melanomas.
    Hill HZ; Hill GJ; Miller CL; Pfaller M; Weiss K; Galin M
    Cancer Res; 1979 Mar; 39(3):934-9. PubMed ID: 427782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [DTIC in malignant melanoma: a perspective (author's transl)].
    Kokoschka EM
    Wien Klin Wochenschr; 1978 Dec; 90(24):870-4. PubMed ID: 369152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents.
    Hill RP; Stanley JA
    Cancer Res; 1975 May; 35(5):1147-53. PubMed ID: 1120304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.
    Slagel DE; Feola J; Houchens DP; Ovejera AA
    Cancer Res; 1982 Mar; 42(3):812-6. PubMed ID: 7059979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human malignant melanoma: preclinical and clinical drug evaluation.
    Osieka R
    Behring Inst Mitt; 1984 May; (74):353-67. PubMed ID: 6383327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Application to chemosensitivity tests of the human tumor-nude mouse system and subrenal capsule assay system].
    Fujita M; Fujita F; Shimozuma K; Sakamoto Y; Kusuyama T; Usugane M; Origasa H; Taguchi T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1227-34. PubMed ID: 3729446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitrosoureas: a review of experimental antitumor activity.
    Schabel FM
    Cancer Treat Rep; 1976 Jun; 60(6):665-98. PubMed ID: 782694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas.
    Hill HZ; Hill GJ
    Cancer Res; 1982 Mar; 42(3):838-42. PubMed ID: 7059982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
    Wack C; Kirst A; Becker JC; Lutz WK; Bröcker EB; Fischer WH
    Cancer Immunol Immunother; 2002 Oct; 51(8):431-9. PubMed ID: 12202904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Predictability of preclinical evaluation of anticancer drugs by human gastrointestinal cancer--nude mouse panel].
    Fujita M; Fujita F; Sakamoto Y; Sugimoto T; Shimozuma K; Taguchi T
    Gan To Kagaku Ryoho; 1991 Jul; 18(9):1429-37. PubMed ID: 1854213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a nude mouse tumor model using beta-galactosidase-expressing melanoma cells.
    Dooley TP; Stamp-Cole M; Ouding RJ
    Lab Anim Sci; 1993 Feb; 43(1):48-57. PubMed ID: 7681492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide.
    D'Incalci M; Torti L; Damia G; Erba E; Morasca L; Garattini S
    Cancer Res; 1983 Dec; 43(12 Pt 1):5674-80. PubMed ID: 6357429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic response of human tumor xenografts in athymic mice to doxorubicin.
    Giuliani FC; Zirvi KA; Kaplan NO
    Cancer Res; 1981 Jan; 41(1):325-35. PubMed ID: 7448772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DTIC (NSC-45388) in malignant melanoma: a perspective.
    Comis RL
    Cancer Treat Rep; 1976 Feb; 60(2):165-76. PubMed ID: 769969
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 44.